Navigation Links
New drug shows promise against multiple sclerosis
Date:11/1/2011

An experimental drug called Ocrelizumab has shown promise in a Phase 2 clinical trial involving 220 people with multiple sclerosis (MS), an often debilitating, chronic autoimmune disease that affects an increasing number of people in North America. It usually strikes young adults and is more common in women than in men.

The study, carried out by researchers at the University of California, San Francisco (UCSF) Medical Center, and involving hospitals in the United States, Canada, and Europe, is described this week in the British medical journal Lancet.

The study involved patients with relapsing-remitting MS, a form of the disease marked by the accumulation of lesions in the brain and spinal cord and periodic "attacks" of neurological impairment.

The 220 patients were randomly enrolled into four groups two that received injections of the monoclonal antibody Ocrelizumab at two different doses, one that received the standard multiple sclerosis drug interferon-beta, and one "control" group that was given a placebo.

The doctors gauged the effectiveness of each treatment by performing monthly magnetic resonance imaging (MRI) brain scans of the patients and counting the number of visible marks that indicate inflamed lesions, a hallmark of the disease. They also compared the severity and frequency of neurological "attacks" that cause loss of vision, incoordination, weakness and numbness, among other symptoms.

The results of this trial showed that patients who received the drug generally fared well and showed fewer signs of the disease than patients who receive a placebo or the standard Interferon treatment. Overall, the trial found that Ocrelizumab led to a 89 percent reduction in the formation of brain lesions, and it also reduced the number of new multiple sclerosis attacks over 24 weeks. During this relatively short-term study, interferon performed no better than placebo on these outcomes.

"It really is
'/>"/>

Contact: Jason Socrates Bardi
jason.bardi@ucsf.edu
415-502-4608
University of California - San Francisco
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. Preterm birth rate shows three year improvement in most states
2. Study shows no increased risk of breast cancer for non-carriers in families with BRCA gene mutation
3. Novel approach to treat proliferative vitreoretinopathy shows promise
4. New therapy shows promise for treating cardiovascular disease
5. More Evidence Shows Newer Forms of Pill Raise Clot Risk, FDA Says
6. New oncolytic virus shows improved effectiveness in preclinical testing
7. Clinical trial shows first evidence that anal cancer is preventable
8. Through-the-nipple breast cancer therapy shows promise in early tests
9. Compound found in common wart treatment shows promise as leukemia therapy
10. Study shows why underrepresented men should be included in binge eating research
11. HIV Medication Patch Shows Promise in Early Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/21/2014)... New York, New York (PRWEB) December 21, 2014 ... http://www.byettalawsuit2013.com/ ) and other product liability claims involving ... as incretin mimetics continue to move forward in ... District Court, Southern District of California, Bernstein Liebhard ... 17th, the Court has established a data cut-off ...
(Date:12/21/2014)... December 21, 2014 AlignLife of Norton ... need while at the same time helping people get their ... non-profit community-based organization committed to serving those persons in Muskegon ... needs to improve the quality of life. Dr. Michael Rykse ... impact in the local community and he knew he found ...
(Date:12/21/2014)... 21, 2014 SCI explores ... issues and systemic barriers for disabled athletes with ... Scheidies has a condition called juvenile macular degeneration, where ... how he adapted his athletic ambitions to his vision ... in triathlon to pioneer the way for other blind ...
(Date:12/21/2014)... 2014 The Oncology Institute of Hope and ... Ana and Whittier offices. The Hope for the Holidays Toy ... patients and their families during the holiday season. This year, ... 70 children between both offices. This event continues to be ... community service team, store managers and assistant managers came out ...
(Date:12/20/2014)... 21, 2014 MissyDress, a distinguished special ... prom lovers. The business has drastically cut prices to ... to everyone until Jan. 30, 2015. Many of the ... dresses, V-neck dresses, lace dresses, and more. , A ... there every day. Whether A-line princess prom dresses or ...
Breaking Medicine News(10 mins):Health News:Byetta Lawsuit News: New Order Issued in Federal Incretin Mimetics Litigation, Bernstein Liebhard LLP Report 2Health News:Byetta Lawsuit News: New Order Issued in Federal Incretin Mimetics Litigation, Bernstein Liebhard LLP Report 3Health News:Byetta Lawsuit News: New Order Issued in Federal Incretin Mimetics Litigation, Bernstein Liebhard LLP Report 4Health News:AlignLife of Norton Shores Makes a Brighter Christmas for Kids in Muskegon 2Health News:Disability in Sports on SCI TV with Triathlon World Champ Aaron Scheidies 2Health News:Disability in Sports on SCI TV with Triathlon World Champ Aaron Scheidies 3Health News:MissyDress: The Prices of Prom Dresses Just Reduced 2
... on findings of a recent study researchers say the ... risk of heart attack. For the study researchers looked ... who had never had a heart attack when the ... a history of taking a nonsteroidal anti-inflammatory drug (NSAID). ...
... say a non-surgical treatment is just as good as ... carpel tunnel syndrome. Carpal tunnel syndrome is a painful ... median nerve that runs from the base of the ... repetitive hand motions, including computer users, dental hygienists, and ...
... A new evaluation tool can predict the mortality risk in ... // of a recent study. According to researchers the new ... treatment of acute heart failure and offers a simple, quick ... and quickly decide on a treatment strategy. ,Researchers used ...
... probe being developed, screening women for cervical cancer could be ... into the vagina, and the woman herself can do it. ... electrical resistance. ,It is so small that women ... taking up the routine Pap smear that is being done. ...
... patients with Crohn's disease do not have improved bone ... vitamin D therapy. Crohn's is an inflammatory bowel disease ... It usually begins in the teenage years and is ... with Crohn's disease suffer bone mass loss and bone ...
... least six-times more likely to kill high-risk women compared to ... of a recent study . ,8,353 women who had ... diabetes or multiple risk factors were studied. The women were ... cholesterol levels. ,Researchers found only 7 percent of the ...
Cached Medicine News:
(Date:12/19/2014)... -- TODAY, AEGATE, the leader in medicine ... appointment of Peter Fox as Chief Technology ... Partner Officer. Peter has served as Development ... by Oracle in 2011. Prior to Datanomic, ... and subsequently Convergys, a world renowned billing system ...
(Date:12/19/2014)... BOCA RATON, Fla. , Dec. 19, 2014 /PRNewswire/ ... entered into a multi-product agreement with MSN Laboratories Pvt. ... Breckenridge and MSN expect to commercialize several new ANDAs. ... manufacture, and supply the products exclusively to Breckenridge for ... the products under its label.  Breckenridge and MSN have ...
(Date:12/19/2014)... , Dec. 19, 2014  Monarch America Inc. (OTCQB: ... Corp.) is pleased to provide this review of the ... in 2015. "Over this past year, we ... I am extremely proud to say that Monarch America ... than it has ever been," stated Eric Hagen ...
Breaking Medicine Technology:Aegate Appoints new CTO and Chief Channels & Partner Officer 2Aegate Appoints new CTO and Chief Channels & Partner Officer 3Aegate Appoints new CTO and Chief Channels & Partner Officer 4Breckenridge Pharmaceutical signs Multi-Product Generic Agreement with MSN Laboratories Pvt. Ltd. 2Monarch America Inc. CEO Reviews Recent Achievements and Provides Outlook for 2015 2Monarch America Inc. CEO Reviews Recent Achievements and Provides Outlook for 2015 3
... MYL ) today announced that it has notified The ... (Nasdaq: NDAQ ), that it intends to voluntarily de-list ... Market, on which the notes trade under the ticker symbol "MYLNG," ... The notes will continue to trade over-the-counter (OTC) with trade data ...
... Ultra Clean Holdings, Inc. (Nasdaq: UCTT ), ... semiconductor capital equipment, medical device, energy, research, and flat ... Executive Officer, and Casey Eichler, Chief Financial Officer, will ... will take place at the New York Palace Hotel, ...
Cached Medicine Technology:Mylan Announces Voluntary De-listing of 1.25% Senior Convertible Notes Due 2012 from Nasdaq 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: